S
INBX icon

SignatureFD’s Inhibrx INBX Stock Holding History

SignatureFD’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01K Buy
15
+13
+650% +$964 ﹤0.01% 3210
2025
Q4 		$158 Hold
2
– – ﹤0.01% 3316
2025
Q3 		$67 Hold
2
– – ﹤0.01% 3329
2025
Q2 		$29 Sell
2
-40
-95% -$517 ﹤0.01% 3222
2025
Q1 		$588 Sell
42
-86
-67% -$1.17K ﹤0.01% 3147
2024
Q4 		$1.97K Sell
128
-58
-31% -$883 ﹤0.01% 2874
2024
Q3 		$2.91K Hold
186
– – ﹤0.01% 2728
2024
Q2 		$2.64K Buy
+186
New +$2.91K ﹤0.01% 2689

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SignatureFD's INBX Position: Q1 2026 in Review

SignatureFD increased its Inhibrx (INBX) stake by 650% in Q1 2026, buying an estimated $964 and bringing the position to 15 shares worth $1.01K. The position accounts for ﹤0.01% of the portfolio, ranked #3210.

SignatureFD first reported a position in INBX in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.91K in Q3 2024. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • SignatureFD held 15 shares of Inhibrx worth $1.01K as of Q1 2026.
  • SignatureFD bought 13 Inhibrx shares in Q1 2026, an estimated $964.
  • Inhibrx made up ﹤0.01% of SignatureFD's portfolio in Q1 2026, its #3210 holding.
  • SignatureFD first reported a position in Inhibrx in Q2 2024 and has held it in 8 quarters since.
  • SignatureFD's Inhibrx position peaked at $2.91K in Q3 2024.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.